TLP
BTAI icon

Tri Locum Partners’s BioXcel Therapeutics BTAI Stock Holding History

Tri Locum Partners’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-602
Closed -$445K – 43
2020
Q4 		$445K Buy
+602
New +$469K 0.16% 40

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tri Locum Partners's BTAI Position: Q1 2021 in Review

Tri Locum Partners sold out of BioXcel Therapeutics (BTAI) in Q1 2021, closing a stake of 602 shares — an estimated $445K sold.

Tri Locum Partners first reported a position in BTAI in Q4 2020 and held it in 1 quarter. The position peaked at $445K in Q4 2020. 116 funds tracked by Wall St. Rank hold BTAI as of Q1 2021.

  • Tri Locum Partners reported no remaining BioXcel Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Tri Locum Partners sold 602 BioXcel Therapeutics shares in Q1 2021, an estimated $445K.
  • Tri Locum Partners first reported a position in BioXcel Therapeutics in Q4 2020 and held it in 1 quarter.
  • Tri Locum Partners's BioXcel Therapeutics position peaked at $445K in Q4 2020.
  • 116 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2021.

Based on Tri Locum Partners's 13F filing for Q1 2021, filed 17 May 2021.